<?xml version="1.0" encoding="UTF-8"?>
<p id="para0077">Azithromycin is a macrolide antibiotic. Previous 
 <italic>in vitro</italic> studies revealed the antiviral activity of azithromycin and also it could prevent severe viral respiratory tract infections in patients infected with respiratory viruses. A recent publication showed that azithromycin in combination with hydroxychloroquine could have synergistic effects against COVID-19 infection. But the most important concern about these two compounds is the increased risk of QT prolongation and Torsades de points.
 <xref rid="bib0042" ref-type="bibr">
  <sup>42</sup>
 </xref> especially in patients with underlying cardiovascular diseases. So, close patient monitoring is required during the concomitant administration. An open-label non-randomized clinical trial in France revealed that co-administration of azithromycin with hydroxychloroquine in COVID-19 patients was accompanied by reinforcement of the effect of hydroxychloroquine monotherapy, but the main limitation of this clinical trial was its small sample size.
 <xref rid="bib0042" ref-type="bibr">
  <sup>42</sup>
 </xref> So, further larger clinical trials are required to confirm these combinationsâ€™ safety and efficacy in COVID-19 treatment.
</p>
